Bli medlem
Bli medlem

Du är här


Episurf Medical publishes prospectus regarding the admission to trading of new shares of series B on Nasdaq Stockholm

This press release may not be made public, published or distributed, directly or indirectly, in whole or in part, within or to the United States, Australia, Hong Kong, Japan, Canada, New Zealand, Switzerland, Singapore, South Africa or any other jurisdiction where such action would be unlawful or subject to legal restrictions.

Episurf Medical AB (publ) ("Episurf Medical" or the "Company") has on 14 October 2021, based on the authorisation granted by the Annual General Meeting on 10 May 2021, carried out a directed issue of 44,408,108 new shares of series B (the "Share Issue"). The Share Issue was directed mainly to Health Runner AB, a company controlled by Ilija Batljan, and in addition to a limited number of institutional investors.

The Company has prepared a prospectus regarding the Company's application for admission to trading of the new shares of series B on Nasdaq Stockholm, which has today been approved and registered with the Swedish Financial Supervisory Authority in accordance with Regulation (EU) 2017/1129 of the European Parliament and of the Council of 14 June 2017. The prospectus is available at the Company's website ( and will also be available via the Swedish Financial Supervisory Authority's website ( The new shares of series B are expected to be admitted to trading on Nasdaq Stockholm on or around 30 November 2021.

Zonda Partners AB has acted as financial advisor and Hannes Snellman Attorneys Ltd has acted as legal advisor in connection with the Share Issue. Eminova Fondkommission AB is settlement agent for the Share Issue.

For more information, please contact:

Pål Ryfors, CEO, Episurf Medical
Tel:+46 (0) 709 62 36 69

Veronica Wallin, CFO, Episurf Medical
Tel:+46 (0) 700 37 48 95
Email: (

Författare Cision